Latest Insider Transactions at Quest Diagnostics Inc (DGX)
This section provides a real-time view of insider transactions for Quest Diagnostics Inc (DGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of QUEST DIAGNOSTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of QUEST DIAGNOSTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 05
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
44,939
-52.81%
|
$6,156,643
$137.0 P/Share
|
|
May 05
2021
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
44,939
+34.56%
|
$3,190,669
$71.17 P/Share
|
|
Mar 10
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,574
-12.19%
|
$668,880
$120.47 P/Share
|
|
Mar 09
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
6,165
-16.93%
|
$708,975
$115.42 P/Share
|
|
Mar 09
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
13,181
+26.59%
|
$1,515,815
$115.42 P/Share
|
|
Mar 09
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,334
-14.3%
|
$958,410
$115.42 P/Share
|
|
Mar 09
2021
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
16,570
+22.14%
|
$1,905,550
$115.42 P/Share
|
|
Mar 09
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
5,066
-6.15%
|
$582,590
$115.42 P/Share
|
|
Mar 09
2021
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
11,299
+12.07%
|
$1,299,385
$115.42 P/Share
|
|
Mar 09
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,403
-6.73%
|
$736,345
$115.42 P/Share
|
|
Mar 09
2021
|
Mark Guinan Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,322
+15.4%
|
$1,992,030
$115.42 P/Share
|
|
Mar 09
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-2.49%
|
$78,660
$115.42 P/Share
|
|
Mar 09
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,884
+6.41%
|
$216,660
$115.42 P/Share
|
|
Mar 09
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,217
-8.44%
|
$484,955
$115.42 P/Share
|
|
Mar 09
2021
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+16.39%
|
$1,125,965
$115.42 P/Share
|
|
Mar 09
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
25,887
-8.34%
|
$2,977,005
$115.42 P/Share
|
|
Mar 09
2021
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
58,368
+15.83%
|
$6,712,320
$115.42 P/Share
|
|
Feb 25
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
801
-1.96%
|
$92,115
$115.49 P/Share
|
|
Feb 24
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.73%
|
$63,404
$121.19 P/Share
|
|
Feb 24
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,319
-1.3%
|
$401,599
$121.19 P/Share
|
|
Feb 24
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.69%
|
$65,461
$121.19 P/Share
|
|
Feb 24
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
611
-2.56%
|
$73,931
$121.19 P/Share
|
|
Feb 24
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.4%
|
$12,463
$121.19 P/Share
|
|
Feb 24
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,188
-1.42%
|
$137,808
$116.95 P/Share
|
|
Feb 24
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
455
-1.07%
|
$55,055
$121.19 P/Share
|
|
Feb 24
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
806
-1.9%
|
$97,526
$121.19 P/Share
|
|
Feb 23
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
796
-1.1%
|
$96,316
$121.15 P/Share
|
|
Feb 23
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,033
-1.56%
|
$487,993
$121.15 P/Share
|
|
Feb 23
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
830
-1.05%
|
$100,430
$121.15 P/Share
|
|
Feb 23
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-4.09%
|
$123,057
$121.15 P/Share
|
|
Feb 23
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
159
-0.61%
|
$19,239
$121.15 P/Share
|
|
Feb 23
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-1.6%
|
$83,853
$121.15 P/Share
|
|
Feb 23
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,250
-2.86%
|
$151,250
$121.15 P/Share
|
|
Feb 17
2021
|
Manuel O. Mendez SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,926
+14.5%
|
-
|
|
Feb 17
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
4,926
+16.55%
|
-
|
|
Feb 17
2021
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
5,665
+11.46%
|
-
|
|
Feb 17
2021
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,941
+5.17%
|
-
|
|
Feb 17
2021
|
Mark Guinan Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,665
+6.67%
|
-
|
|
Feb 17
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
715
+2.69%
|
-
|
|
Feb 17
2021
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,202
+6.89%
|
-
|
|
Feb 17
2021
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,551
+7.67%
|
-
|
|
Jan 04
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,640
-11.71%
|
$314,160
$119.0 P/Share
|
|
Dec 24
2020
|
Mark Guinan Executive Vice President & CFO |
SELL
Open market or private sale
|
Direct |
81,756
-30.79%
|
$9,810,720
$120.62 P/Share
|
|
Dec 24
2020
|
Mark Guinan Executive Vice President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
81,756
+34.48%
|
$5,395,896
$66.51 P/Share
|
|
Nov 24
2020
|
Gail R Wilensky Director |
SELL
Open market or private sale
|
Direct |
6,111
-27.05%
|
$769,986
$126.02 P/Share
|
|
Nov 24
2020
|
Gail R Wilensky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,111
+21.29%
|
$348,327
$57.66 P/Share
|
|
Nov 23
2020
|
Daniel Stanzione Director |
SELL
Open market or private sale
|
Direct |
11,223
-10.48%
|
$1,414,098
$126.55 P/Share
|
|
Oct 21
2020
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Open market or private sale
|
Direct |
10,450
-15.99%
|
$1,306,250
$125.0 P/Share
|
|
Oct 21
2020
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,450
+13.8%
|
$595,650
$57.21 P/Share
|
|
Oct 16
2020
|
Stephen H Rusckowski Director |
SELL
Open market or private sale
|
Direct |
291,997
-55.12%
|
$35,039,640
$120.0 P/Share
|